Obsessive compulsive disorder (OCD) is a mental disorder that is characterized by intrusive thoughts or images that lead to feelings of anxiety and distress. It affects up to 2.3% of the global population and is a common psychiatric disorder among adults. As such, there is a need to identify effective treatments for ocd trials biohaven. Biohaven Pharmaceuticals, a biopharmaceutical company based in the United States, is currently running clinical trials to assess the efficacy of their drug, BHV-3500, in treating OCD.
The BHV-3500 trial is a 12-week, randomized, double-blind, placebo-controlled study. The trial has enrolled over 350 participants from the United States and Canada and will assess the efficacy of BHV-3500 in reducing the severity of OCD symptoms. Participants will be randomly assigned to receive either BHV-3500 or a placebo over the course of the trial. The primary outcome measure that will be used to assess the efficacy of BHV-3500 is the Yale-Brown Obsessive Compulsive Scale, a measure of OCD symptom severity.
Image Source: Google
In addition to the primary outcome measure, secondary measures will also be used to assess the safety and tolerability of BHV-3500. This includes measures such as adverse events, vital signs, and clinical laboratory tests. The data collected during the trial will be used to assess the efficacy and safety of BHV-3500 and will help inform future studies.
The results of the BHV-3500 trial are expected to be available in the first half of 2021. If successful, BHV-3500 could become an important treatment option for people with OCD, providing relief from the intrusive thoughts and distress that are associated with the disorder.
In conclusion, Biohaven’s BHV-3500 trial is an important step in the development of effective treatments for OCD. The trial is currently enrolling participants and is expected to provide results in the first half of 2021. If successful, BHV-3500 could become an important treatment option for those suffering from OCD.